The bulk of the selling comes from FMR LLC, a top-10 holder, which is unusual for a passive 13G filer and suggests a rebalancing or conviction shift. The CEO's sales are option-exercise-driven and not a standalone bearish signal. However, the FMR sale alone warrants monitoring for additional filing or quiet-period updates. The lack of a strong directional catalyst means the market may not react sharply. Consider the historical poor performance of BEAM reports and avoid a directional bet based on this cluster alone.
Price Chart
Executive Summary
A cluster of insider selling at Beam Therapeutics materialized over June 26-30, 2026, totaling $8.95M. The CEO exercised stock options and sold shares in a typical cashless-exercise pattern, while the 10% owner FMR LLC sold $8.87M — a meaningful 0.26% of market cap. This is a mixed signal: the CEO's trades are routine option exercises, but FMR's large sale is a notable reduction of a top stake. The cluster does not align with a single bearish catalyst, and the historical calibration for BEAM reports has been unprofitable on net, so the impact should be tempered.
Key Financial Metrics
Key Facts
- Total insider cluster value: $8.95M over 5 trading days
- FMR LLC (10% owner) sold 251,488 shares for $8.87M — 0.26% of BEAM's $3.4B market cap
- CEO John M. Evans exercised 100,000 stock options and sold 50,000 shares in a typical cashless-exercise pattern, netting ~$1.75M in open-market sales
- CMO Amy Simon sold 373 shares for $13K — trivial amount
- Only 3 unique insiders traded, with the CEO's sales all directly tied to option exercises (not outright directional selling)
- Historical BEAM reports have a T+20 net P&L of +0.45% but a negative alpha of -1.86% vs SPY, with only a 43% win rate — prior high-score calls (7-8) have been mixed
- Score calibration shows observed P for score-7 calls is low (~31-39%), suggesting the market does not heavily react to directional BEAM reports at this score level
Financial Impact
FMR's sale of $8.87M represents a 0.26% reduction of a major institutional stake; CEO sales total ~$1.75M, largely linked to option exercises. The total cluster value of $8.95M is 0.26% of market cap, falling in the modest range (0.1-0.5%) but concentrated in a single institutional seller.
Risk Factors
- FMR's large sale could precede further institutional distribution, creating near-term overhead supply
- CEO and CMO selling in same window may rattle retail perception despite being routine
- No documented bearish corporate catalyst (no earnings miss, no guidance cut, no pipeline setback); FMR's motives are opaque
- Historical BEAM reports have negative alpha vs SPY and low win rate, suggesting limited edge
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BEAM-1783022742041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 15, 2026 6w ago | Institutional Cluster | $27.10 $23.22 | ▼ −14.32% | ▼ −12.34% | $24.50 (−9.59%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.79 $26.49 | ▼ −23.86% | ▼ −23.44% | $24.50 (−29.58%) |
Jul 1, 2026 13w ago | Insider Cluster | $33.48 $26.02 | ▲ +22.28% | ▲ +20.10% | $24.50 (+26.82%) |
May 12, 2026 20w ago | Press Release | $31.58 $29.49 | ▼ −6.62% | ▼ −4.89% | $24.50 (−22.42%) |
Apr 17, 2026 24w ago | DEFA14A | $31.19 $26.81 | ▼ −14.04% | ▼ −18.25% | $24.50 (−21.45%) |
Mar 25, 2026 27w ago | Press Release | $23.12 $30.16 | ▲ +30.45% | ▲ +22.59% | $24.50 (+5.97%) |
Mar 5, 2026 30w ago | 8-K | $26.54 $24.23 | ▼ −8.70% | ▼ −6.66% | $24.50 (−7.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access